(NASDAQ: RVMD) Revolution Medicines's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.15%.
Revolution Medicines's earnings in 2026 is -$1,768,285,000.On average, 25 Wall Street analysts forecast RVMD's earnings for 2026 to be -$1,748,642,233, with the lowest RVMD earnings forecast at -$1,877,844,225, and the highest RVMD earnings forecast at -$1,620,383,320. On average, 24 Wall Street analysts forecast RVMD's earnings for 2027 to be -$1,292,941,574, with the lowest RVMD earnings forecast at -$2,255,933,667, and the highest RVMD earnings forecast at $216,051,109.
In 2028, RVMD is forecast to generate -$487,936,856 in earnings, with the lowest earnings forecast at -$1,459,845,343 and the highest earnings forecast at $1,528,111,492.